(S)-nicardipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 5 76093-36-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • (S)-nicardipine
  • (-)-Nicardipine
S-enantiomer of nicardipine is a calcium entry blocker (slow channel blocker or calcium ion antagonist) which inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations
  • Molecular weight: 479.53
  • Formula: C26H29N3O6
  • CLOGP: 5.23
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 1
  • TPSA: 111.01
  • ALOGS: -5.29
  • ROTB: 11

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 4.302 Moderate 0.72
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.574 Moderate 0.72
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 18.621 10^-6 cm/s Moderate 0.72
dh-clint Dog hepatocyte intrinsic clearance 168.655 uL/min/10^6 cells Moderate 0.72
dppb Dog plasma protein binding (% unbound) 0.480 % Moderate 0.72
fcs-ppb Fetal calf serum protein binding (% unbound) 1.280 % Moderate 0.72
herg hERG pIC50 5.715 pIC50 Moderate 0.72
hh-clint Human hepatocyte intrinsic clearance 172.187 uL/min/10^6 cells Moderate 0.72
hlm-clint Human liver microsomal intrinsic clearance 295.121 uL/min/mg protein Moderate 0.72
hppb Human plasma protein binding (% unbound) 0.510 % Moderate 0.72
kinase-safety-class ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK,ZAP70 42
kinase-selectivity-class AXL,BRAF,CDK9,GRK2,MAPK7,STK33,TEK 7
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.612 Moderate 0.72
mh-clint Mouse hepatocyte intrinsic clearance 216.770 Moderate 0.72
mppb Mouse plasma protein binding (% unbound) 0.470 Moderate 0.72
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 9.247 Moderate 0.72
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 0.950 % Moderate 0.72
rh-clint Rat hepatocyte intrinsic clearance 276.694 uL/min/10^6 cells Moderate 0.72
rh-fuinc Rat hepatocyte fraction unbound in incubation 5.470 % Moderate 0.72
rppb Rat plasma protein binding (% unbound) 0.490 % Moderate 0.72
solubility-dd Solubility at pH 7.4 in DMSO 3.083 uM Moderate 0.72

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:38215 calcium channel blocker

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.02 Basic
pKa2 2.37 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Voltage-gated L-type calcium channel Ion channel BLOCKER DRUG LABEL DRUG LABEL

External reference:

IDSource
6604415 PUBCHEM_CID
CHEBI:180904 CHEBI
3JT3BYK2JW UNII
8LAW0NT30I UNII

Pharmaceutical products:

None